Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
L Wollin, JHW Distler, EF Redente… - European …, 2019 - Eur Respiratory Soc
A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive
phenotype characterised by decline in lung function, worsening quality of life and early …
phenotype characterised by decline in lung function, worsening quality of life and early …
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
L Wollin, JHW Distler, EF Redente… - European Respiratory …, 2019 - cir.nii.ac.jp
抄録< jats: p> A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop
a progressive phenotype characterised by decline in lung function, worsening quality of life …
a progressive phenotype characterised by decline in lung function, worsening quality of life …
[PDF][PDF] Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
L Wollin, JHW Distler, EF Redente, DWH Riches… - Eur Respir J, 2019 - qdcxjkg.com
ABSTRACT A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a
progressive phenotype characterised by decline in lung function, worsening quality of life …
progressive phenotype characterised by decline in lung function, worsening quality of life …
Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases
L Wollin, JHW Distler, EF Redente… - European …, 2019 - Eur Respiratory Soc
A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive
phenotype characterised by decline in lung function, worsening quality of life and early …
phenotype characterised by decline in lung function, worsening quality of life and early …
[HTML][HTML] Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
L Wollin, JHW Distler, EF Redente… - The European …, 2019 - ncbi.nlm.nih.gov
A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive
phenotype characterised by decline in lung function, worsening quality of life and early …
phenotype characterised by decline in lung function, worsening quality of life and early …
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
L Wollin, JHW Distler, EF Redente… - The European …, 2019 - pubmed.ncbi.nlm.nih.gov
A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive
phenotype characterised by decline in lung function, worsening quality of life and early …
phenotype characterised by decline in lung function, worsening quality of life and early …
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
L Wollin, JHW Distler, EF Redente… - The European …, 2019 - europepmc.org
A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive
phenotype characterised by decline in lung function, worsening quality of life and early …
phenotype characterised by decline in lung function, worsening quality of life and early …
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
L Wollin, JHW Distler, EF Redente… - The European …, 2019 - europepmc.org
A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive
phenotype characterised by decline in lung function, worsening quality of life and early …
phenotype characterised by decline in lung function, worsening quality of life and early …
[PDF][PDF] Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
L Wollin, JHW Distler, EF Redente, DWH Riches… - Eur Respir J, 2019 - qdcxjkg.com
ABSTRACT A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a
progressive phenotype characterised by decline in lung function, worsening quality of life …
progressive phenotype characterised by decline in lung function, worsening quality of life …